Quipt Home Medical Corp. Stock

Equities

QIPT

CA74880P1045

Healthcare Facilities & Services

Market Closed - Toronto S.E. 03:59:51 2024-04-26 pm EDT 5-day change 1st Jan Change
4.98 CAD -0.60% Intraday chart for Quipt Home Medical Corp. -2.92% -26.22%
Sales 2024 * 361M 264M Sales 2025 * 392M 287M Capitalization 213M 156M
Net income 2024 * - 0 Net income 2025 * 9M 6.58M EV / Sales 2024 * 0.59 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.54 x
P/E ratio 2024 *
144 x
P/E ratio 2025 *
24.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.08%
More Fundamentals * Assessed data
Dynamic Chart
Quipt Home Medical Maintained at Buy at Stifel GMP After Fiscal Q1 Results; Price Target Cut to C$10.50 MT
Transcript : Quipt Home Medical Corp., Q1 2024 Earnings Call, Feb 15, 2024
Quipt Home Medical Corp. Brief: Revenue for Q1 2024 was US$65.4 million compared to $40.8 million for Q1 2023; Net income (loss) for Q1 2024 was $(0.6) million, or ($0.01) per diluted share MT
Quipt Home Medical Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
North American Morning Briefing :Stock Futures -2- DJ
Quipt Home Medical Corp. Brief: Shelf Prospectus and Registration Statement, when made final and effective, will enable Co to offer Up to C$300,000,000 of common shares, preferred shares, debt securities, warrants MT
Quipt Home Medical Corp. Brief: Announced Filing of Preliminary Base Shelf Prospectus to Replace Recently Expired Base Shelf Prospectus MT
Transcript : Quipt Home Medical Corp., Q4 2023 Earnings Call, Dec 19, 2023
Quipt Home Medical Corp. Up 3% In US After Hours Despite Q4 Net Loss; But Revs and Recurring Revs "Very Strong" MT
Quipt Home Medical Corp. Brief: Adds Company "Maintains a conservative balance sheet" with net debt to Adjusted EBITDA leverage of 1.4x MT
Quipt Home Medical Corp. Brief: Says Recurring Revenue for Q4 2023 was "Very Strong" and Exceeded 83% of total revenue, driven by growth in the Company's resupply platform MT
Quipt Home Medical Corp. Brief: Revenue for Q4 2023 was US$62.5 million compared to $40.1 million for Q4 2022, representing a 56% increase MT
Quipt Home Medical Corp. Brief: Net Loss for Q4 2023 was US($1.3) million, or ($0.03) per diluted share, as compared to $1.8 million, or $0.05 per diluted share for Q4 2022 MT
Quipt Home Medical Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
More news
1 day-0.60%
1 week-2.92%
Current month-15.88%
1 month-15.45%
3 months-20.19%
6 months-21.33%
Current year-26.22%
More quotes
1 week
4.72
Extreme 4.72
5.32
1 month
4.70
Extreme 4.7
5.99
Current year
4.70
Extreme 4.7
6.98
1 year
4.70
Extreme 4.7
8.86
3 years
4.70
Extreme 4.7
9.75
5 years
1.88
Extreme 1.88
10.16
10 years
1.50
Extreme 1.5
10.16
More quotes
Managers TitleAgeSince
Chief Executive Officer - 16-04-18
Director of Finance/CFO - 18-02-14
Chief Tech/Sci/R&D Officer - 09-12-31
Members of the board TitleAgeSince
Chief Executive Officer - 16-04-18
Director/Board Member - 17-12-20
Director/Board Member - 20-12-06
More insiders
Date Price Change Volume
24-04-25 5.01 -4.75% 20,700
24-04-24 5.26 +0.19% 14,766
24-04-23 5.25 +2.34% 18,674
24-04-22 5.13 +8.23% 46,987
24-04-19 4.74 -1.04% 29,150

Delayed Quote Toronto S.E., April 26, 2024 at 03:59 pm EDT

More quotes
Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.01 CAD
Average target price
13.42 CAD
Spread / Average Target
+167.80%
Consensus